Answers are grounded in this paper and cite their sources.
Narrative review evaluates simian adenoviral vaccine platforms across clinical trials, highlighting their capacity to bypass pre-existing immunity while driving robust immune responses.
Replication incompetent human adenovirus serotype 5 (HAdV-C5) has been extensively used as a delivery vehicle for gene therapy proteins and infectious disease antigens. These vectors infect replicating and nonreplicating cells, have a broad tissue tropism, elicit high immune responses and are easily purified to high titers. However, the utility of HAdV-C5 vectors as potential vaccines is limited due to pre-existing immunity within the human population that significantly reduces the immunogenicity of HAdV-C5 vaccines. In recent years, adenovirus vaccine development has focused on simian-derived adenoviral vectors, which have the desirable vector characteristics of HAdV-C5 but with negligible seroprevalence in the human population. Here, we discuss recent advances in simian adenovirus vaccine vector development and evaluate current research specifically focusing on clinical trial data.
No takes yet. Share an insight, caveat, or question.
Morris et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: